“The Immuno-Oncology Curve” with Dr. Steven O’Day – Guests are Dr. Joseph Grossman and Dr. Benny Johnson
Steven O’Day, the Chief Medical Officer of Agenus, shared on LinkedIn:
“In the latest episode of my podcast, ‘The Immuno-Oncology Curve‘, I’m joined by my Agenus colleagues Dr. Joseph Grossman and Dr. Benny Johnson. We talk about why we left the practice of medicine for Agenus.
And, we reflect on this year’s ASCO GI Cancers Symposium, covering the rise of early-onset cancers, the promising use of circulating tumor DNA (ctDNA) as a biomarker, the ongoing challenge of diversity in cancer clinical trials, and the overall potential of I-O to reduce dependence on chemotherapy and surgery.”
Proceed to the podcast.
Source: Steven O’Day/LinkedIn
Steven O’Day serves as Agenus’ Chief Medical Officer. He is responsible for leading the expansion of the company’s presence in the I-O field. A pioneer in CTLA-4 inhibition, Dr O’Day played key roles in the advancement of cancer therapies Yervoy and Opdivo, and has been the principal investigator in more than 200 clinical trials. Prior to joining Agenus, he was Executive Director of the John Wayne Cancer Institute and Cancer Clinics at Providence St. John’s Health Center, and Director of the Melanoma and Cutaneous Oncology Research Center. Steven was a visiting scholar in philosophy and medical ethics at Oxford, received his MD from Johns Hopkins, and was a Fellow at the Dana Farber/Harvard Cancer Center.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023